|
 |
Brimonidine tartrateThis page contains recent news articles, when available, and an overview of Brimonidine tartrate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Brimonidine tartrate (when available) Brimonidine significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. It lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow. For the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Mechanism Of Action: Brimonidine is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. News Articles on Brimonidine Experimental and Clinical Evidence for Brimonidine as an Optic ... - Apr 13, 2009 Objective To review the available evidence for the neuroprotective qualities of brimonidine tartrate in optic nerve and retinal injury. Archives of Ophthalmology Lotus Pharma Reports Solid 2008 but Still Lacks Cash - Apr 17, 2009 On the revenue front, Lotus said the increase was derived from increased sales of its own Brimonidine Tartrate Eye Drops and a number of third-party Seeking Alpha Court Report - Apr 12, 2009 ...of an ANDA to manufacture a generic version of Allergan's Combigan® (brimonidine tartrate/timolol maleate ophthalmic solution, used to treat glaucoma). Patent Docs Lotus Increases Profit In Q3 While Revenues Drop - Nov 18, 2008 Lotus said that strong revenues from its newest drug, Brimonidine Tartrate Eye Drops, a glaucoma treatment, were responsible for much of the rise in istockAnalyst.com (press release), Lotus Pharmaceuticals Announces Third Quarter 2008 Results - Nov 18, 2008 This increase was attributable to strong sales for the Company's Brimonidine Tartrate Eye Drops, used in the treatment of glaucoma, and strong sales of a Earthtimes (press release), Lotus Pharmaceuticals Announces Third Quarter 2008 Results - Nov 18, 2008 This increase was attributable to strong sales for the Company's Brimonidine Tartrate Eye Drops, used in the treatment of glaucoma, and strong sales of a PharmaLive.com (press release), Lotus Pharmaceuticals Announces Second Quarter 2008 Results Aug 18, 2008 This increase was because of increased sales of third- party pharmaceuticals and increased sales of the Company's Brimonidine Tartrate Eyes Drops (soldEarthtimes (press release), Lotus Pharmaceuticals Announces Second Quarter 2008 Results Aug 18, 2008 This increase was because of increased sales of third- party pharmaceuticals and increased sales of the Company's Brimonidine Tartrate Eyes Drops (soldBiloxi Sun Herald, Allergan reports 20.1% rise in second-quarter product sales - Aug 1, 2008 Alphagan P (brimonidine tartrate 0.15%), Alphagan (brimonidine tartrate) and Combigan (0.2% brimonidine tartrate, 0.5% timolol maleate) sales totaled OSN SuperSite (subscription), Hyperemia in Glaucoma Patients - Jul 25, 2008 Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma. 2004;13:163-167. Medscape (subscription) Lotus plant sows seeds for growth - Jul 29, 2008 Last year's key earners included the vasodilator valsartan, the glaucoma drug brimonidine tartrate, the antibacterial levofloxacin and nicergoline for In-PharmaTechnologist.com, Intoxicación por brimonidina en pediatría. Presentación como ... - Jul 22, 2008 Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2 % and timolol 0.5 % given twice daily in patients with glaucoma or Anales de Pediatría, Brimonidine tartrate can successfully reduce halo size and pupil ... - Jun 10, 2008 Ji Hoon Lee, MD, and colleagues evaluated the effect of Alphagan (brimonidine tartrate 0.2%, Allergan) on halo and pupil size after administering the drug OSN SuperSite (subscription), Learn about the World Ophthalmic Pharmaceutical Drugs Market - Jun 27, 2008 1% II-75 Alimera Sciences Unveils Soothe(tm) Emollient Eye Drops II-75 Novartis Introduces Zaditen in Japan II-76 Falcon Releases Brimonidine Tartrate Market Wire (press release) Allergan reports 23% rise in first-quarter total product net sales - May 8, 2008 Alphagan P (brimonidine tartrate 0.15%), Alphagan (brimonidine tartrate) and Combigan (0.2% brimonidine tartrate, 0.5% timolol maleate) sales totaled $99.5 OSN SuperSite (subscription), Lotus Pharmaceuticals, Inc. Announces First Quarter 2008 Results - May 21, 2008 We focused our sales efforts on our top selling products, Brimonidine Tartrate Eyes Drops and VALSARTAN Capsules, and continued to distribute higher-margin, Earthtimes (press release), Lotus Reports Higher Q1 and New Asthma Drug - May 22, 2008 Lotus said that much of that gain was derived from sales of Brimonidine Tartrate Eyes Drops, a drug used to treat glaucoma, and also Valsartan Capsules, istockAnalyst.com, Allergan Reports Fourth Quarter Operating Results - Jan 30, 2008 On October 31, 2007, Allergan announced that the US Food and Drug Administration (FDA) approved COMBIGAN(TM) (brimonidine tartrate/timolol maleate PharmaLive.com (press release), Lotus Pharmaceuticals Inc. Retains CCG Elite - Jan 14, 2008 ...which was Lotus' best selling drug in the first nine months of 2007; Brimonidine tartrate eyes drops for glaucoma; Levofloxacin lactate for infections; CNNMoney.com Allergan, Inc. Receives FDA Approval for COMBIGAN ™ (brimonidine ... - Oct 31, 2007 ...(BUSINESS WIRE)--Allergan, Inc. (NYSE:AGN) today announced that the US Food and Drug Administration has approved COMBIGAN ™ (brimonidine tartrate/timolol Business Wire (press release), Allergan reports $978.7 million in third-quarter product sales - Nov 6, 2007 Specifically, in the third quarter, Alphagan (brimonidine tartrate), Alphagan P (brimonidine tartrate 0.15%) and Combigan (0.2% brimonidine tartrate, OSN SuperSite (subscription), FDA Approves Combigan, New Glaucoma Drug - Oct 31, 2007 Med Headlines - Allergan, Inc has announced that the US Food and Drug Administration has approved its new glaucoma combo drug Combigan (brimonidine tartrate MedHeadlines, Allergan Receives FDA Approval for Combigan - Nov 1, 2007 Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2 percent/0.5 percent is an eye drop that reduces elevated intraocular pressure. FDA news (subscription), Combigan Drops Approved for Glaucoma - Oct 31, 2007 WEDNESDAY, Oct. 31 (healthday News) -- The US Food and Drug Administration has approved Combigan eye drops (brimonidine tartrate/timolol maleate ophthalmic U.S. News & World Report, Allergan granted FDA approval for combination glaucoma medication - Oct 31, 2007 Combigan (0.2% brimonidine tartrate, 0.5% timolol maleate) is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor. OSN SuperSite (subscription), Allergan Wins FDA Approval For Alpha Adrenergic Receptor Agonist ... - Oct 31, 2007 Inc. (AGN | charts | news | powerrating) on Wednesday said that the US Food and Drug Administration approved Combigan or brimonidine tartrate/timolol Trading Markets (press release), Allergan Reports Third Quarter Operating Results - Nov 6, 2007 On October 31, 2007, Allergan announced that the US Food and Drug Administration approved COMBIGAN(TM) (brimonidine tartrate/timolol maleate ophthalmic Genetic Engineering News (press release), Meticulous attention to detail can help prevent or manage surgical ... - Aug 28, 2007 Alphagan (brimonidine tartrate, Allergan) can help reduce some pupils with different lighting conditions and will not constrict, he said. OSN SuperSite (subscription), Genesis Partner Lotus Pharmaceuticals Forecasts Sales Exceeding ... - Jul 25, 2007 Primenewswire (press release),Brimonidine tartrate eye drops for the treatment of glaucoma and ocular hypertension, with annual sales estimated at $4 million. 4. Allergan Announces FDA Issues Approvable Letter for Combigan ... - Dec 22, 2006 PharmaLive.com (press release),COMBIGAN(TM) includes two agents known to reduce IOP - ALPHAGAN(R) (brimonidine tartrate ophthalmic solution 0.2%) and timolol ophthalmic solution 0.5%, Allergan Announces FDA Issues Approvable Letter for Combigan ... - Dec 22, 2006 PharmaLive.com (press release),COMBIGAN(TM) includes two agents known to reduce IOP - ALPHAGAN(R) (brimonidine tartrate ophthalmic solution 0.2%) and timolol ophthalmic solution 0.5%, Centron Experiences Unprecedented Growth: Its First Anniversary Aug 24, 2006 Additionally, Centron was named medical communications agency of record for Combigan? (brimonidine tartrate/timolol maleate), a new product from Allergan. -PharmaLive.com Genesis and Beijing Pharmaceuticals Partner Announce Four New ... May 11, 2006 Exclusive new drug curing open-angle glaucoma, alpha-2 Receptor Excitant-brimonidine tartrate material and eye drops (Muxin) was approved by the State SFDA ... - PharmaLive.com Alcon and Allergan Reach Agreement on Brimonidine 0.15% Patent ... Mar 9, 2006 ...agreement, Allergan will dismiss both suits with prejudice, and also grant Alcon a co-exclusive license with Allergan for brimonidine tartrate 0.15% ophthalmic ... - Genetic Engineering News Akorn Gets FDA OK for Glaucoma Treatment Mar 20, 2006 The approval covers a solution of brimonidine tartrate, the active ingredient in Allergan Inc.'s Alphagan P. The solution works by decreasing the pressure in ... - Houston Chronicle Alcon, Allergan settle patent suit Mar 9, 2006 ...agreement on two infringement suits brought by Allergan whereby Alcon has been granted a co-exclusive license to sell brimonidine tartrate 0.15 percent ... - United Press International Allergan, Alcon settle patent charges Mar 9, 2006 US sales. The agreement allows Alcon an entry into the brimonidine tartrate market nearly a decade before patents expire. The second ... - BusinessWeek Brand Names/Synonyms: Brimonidine tartrate is also known by the following brand names and/or synonymsAlphagan; Alphagan P; Brimonidine; Brimonidine Tartrate; Bromoxidine; CHEMBANK1623 Drug Category: Brimonidine tartrate is categorized under the following by the FDA: Antihypertensive Agents; EENT Drugs; ATC:S01EA05 Dosage Forms: 0.2% solution Absorption: Minimal systemic absorption occurs after ocular insertion. Interactions: -->Interactions for Brimonidine: Although specific drug interaction studies have not been conducted with ALPHAGAN® P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. Alpha-agonists, as a class, may reduce pulse and blood pressure. Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised. Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN® P in humans can lead to resulting interference with the IOP lowering effect. No data on the level of circulating catecholamines after ALPHAGAN® P administration are available. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. Chemical IUPAC Name: 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |